DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Fleseriu M, Petersenn S, Biller BMK. et al.
Long-term efficacy and safety of once-monthly pasireotide in Cushing’s disease: A Phase III extension study.
Clin Endocrinol (Oxf).
2019;
DOI: 10.1111/cen.14081.
Access:
We do not assume any responsibility for the contents of the web pages of other providers.